Cannell & Spears LLC Has $11.41 Million Holdings in Bristol Myers Squibb Company $BMY

Cannell & Spears LLC lessened its position in Bristol Myers Squibb Company (NYSE:BMY) by 6.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 252,914 shares of the biopharmaceutical company’s stock after selling 18,177 shares during the quarter. Cannell & Spears LLC’s holdings in Bristol Myers Squibb were worth $11,406,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at $25,000. Harbor Capital Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares in the last quarter. Total Investment Management Inc. purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth about $40,000. Finally, Bank of Jackson Hole Trust lifted its stake in Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 810 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on BMY. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Citigroup raised their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Leerink Partners upped their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $61.00.

Bristol Myers Squibb Stock Up 0.1%

Shares of Bristol Myers Squibb stock opened at $59.02 on Friday. The firm has a market cap of $120.18 billion, a price-to-earnings ratio of 17.11, a P/E/G ratio of 0.17 and a beta of 0.26. The stock has a 50-day simple moving average of $58.24 and a 200-day simple moving average of $51.43. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.